Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

Randomized clinical trials in non-critically ill COVID-19 patients showed that therapeutic-dose heparin increased survival with reduced organ support as compared with usual-care thromboprophylaxis, albeit with...

Source: BMC Infectious Diseases - October 24, 2023 Category: Infectious Diseases Authors: B. Cosmi, M. Giannella, G. Fornaro, F. Cristini, A. Patacca, A. Castagna, F. Mazzaferri, S. Testa, A. Pan, M. Lupi, P. Brambilla, A. Montineri, S. Frattima, E. G. Bignami, M. Salvetti, G. De Stefano & hellip; Tags: Research Source Type: research